Indication intelligence, analysis and sector perception

Avalanche Biotechnologies (AAVL) acquires Annapurna Therapeutics - combined company renamed Adverum Biotechnologies with a new symbol ADVM

May 12, 2016 11:14am

A real wait and see if the unification message of the platform will “gel” with investors after all the dissention

ADVM is a gene therapy company that focuses on on developing medicines to treat patients who have rare diseases or diseases of the eye, and have limited or burdensome treatment options. Its pipeline consists of AAVL’s existing ophthalmic programs and four new gene therapy based programs, which are focused on Alpha1-antitrypsin (A1AT) deficiency, cardiomyopathy associated with Friedreich’s ataxia, hereditary angioedema and severe allergies.

The Bottom Line; Another also ran?

AAVL completed its previously announced acquisition of all the outstanding shares of Annapurna and, as a result, Annapurna is now a wholly owned subsidiary. Pursuant to the terms of the agreement AAVL issued 14,087,246 shares of common stock <the new shares are not registered> in exchange for all of the issued and outstanding capital stock of Annapurna. The outstanding options or other rights to purchase capital stock of Annapurna were converted into options.

Effective on the closing date, the board of directors appointed Amber Salzman, Ph.D., as President and Chief Operating Officer of the Company, Carlo Russo, M.D., as Executive Vice President and Chief Medical Officer of the Company, Mehdi Gasmi, Ph.D., the Company's current interim Chief Scientific Officer, as Chief Technology Officer of the Company, and Samuel B. Barone, M.D., the Company's current Chief Medical Officer, as Senior Vice President, Clinical Development. Paul B. Cleveland, the Company's current President, Chief Executive Officer and interim Chief Financial Officer, will continue in his positions as Chief Executive Officer and interim Chief Financial Officer and as a member of the board of directors.

AAVL closed Wednesday DOWN -$0.18 at $4.14. On Thursday it is now trading as Adverum Biotechnologies (ADVM) at $4.02 as of 10:45 am.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.